Table 3.

Gastrointestinal, renal, and other adverse events reported in patients receiving the combination of vincristine and antifungal azoles.

Adverse Event	Signs and Symptoms	All Azoles N = 47 (%)	Itra N = 35 (%)	Keto N = 8 (%)	Posa N = 3 (%)	Vori N = 1 (%)
Gastrointestinal		31 (66)	29 (82.9)	1 (12.5)	1 (33.3)	0 (0)
	Abdominal distension		6 (17.1)
	Abdominal pain		15 (42.9)		1 (33.3)
	Constipation		16 (45.7)	1 (12.5)	1 (33.3)
	Ileus		18 (51.4)
	Nausea		2 (5.7)
	Non alcoholic steatohepatitis		2 (5.7)
	Perforation		1 (2.9)
	Vomiting		1 (2.9)
Renal (electrolyte abnormalities)		21 (44.7)	19 (54.3)	0 (0)	2 (66.7)	0 (0)
	Hyponatremia		19 (54.3)		2 (66.7)
	SIADH		13 (37.1)		2 (66.7)
Other		16 (34)	12 (34.3)	2 (25)	2 (66.7)	0 (0)
	Agitation		1 (2.9)	1 (12.5)	1 (33.3)
	Depression		6 (17.1)
	Seizure		8 (22.9)	1 (12.5)	2 (66.7)
	Cerebral edema				1 (33.3)

itra = itraconazole;keto=ketoconazole; posa = posaconazole;vori = voriconazole;N = total number of patients;SIADH = syndrome of inappropriate antidiuretic hormone secretion.